Type 2 diabetic nephropathy: never too early to treat?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Deciphering the Efficacy and Mechanisms of Chinese Herbal Medicine for Diabetic Kidney Disease by Integrating Web-Based Biochemical Databases and Real-World Clinical Data: Retrospective Cohort Study.JMIR medical informatics · 2021
   Article
2. High Glucose Impairs Insulin Signaling in the Glomerulus: An In Vitro and Ex Vivo Approach.PloS one · 2016
   Article
3. The effect of RAAS blockade on the progression of diabetic nephropathy.Nature reviews. Nephrology · 2014
   Review
4. Involvement of vascular endothelial nitric oxide synthase in development of experimental diabetic nephropathy in rats.Molecular and cellular biochemistry · 2011
   Article
5. 6. Diabetic Nephropathy.EJIFCC · 2009
   Article

Corrections and comments

• Comment on
  Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.2005

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as